Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?
about
Allergen-specific immunotherapy: is it vaccination against toxins after all?Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice.Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines.Potential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform.Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE).Specific immunotherapy in children: the evidence.Novel routes for allergen immunotherapy: safety, efficacy and mode of action.The role of immunotherapy in the management of childhood asthma.Emerging drugs for perennial allergic rhinitis.Novel approaches to food allergy.A comparison of immunotherapy delivery methods for allergen immunotherapy.New therapies for allergic rhinitis.Investigational drugs for the treatment of allergic rhinitis.Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.OPINION: Primary prevention of allergy - Will it soon become a reality?Epicutaneous immunotherapy for food allergy as a novel pathway for oral tolerance induction.Allergen immunotherapy in allergic rhinitis: current use and future trends.Therapeutic potential of semi-mature dendritic cells for tolerance induction.Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.Epicutaneous Immunotherapy for Aeroallergen and Food Allergy.Is The Allergen Really Needed in Allergy Immunotherapy?Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model.
P2860
Q30248317-AB582B04-78FA-40EB-BC5C-130A2CB10D91Q34402672-8C4CEB94-7687-4F3D-8365-30ABFD146DE3Q34593082-A0391C4C-E0FE-40D4-B694-BD2FED70749BQ36056484-4610310A-CD21-426E-8D7C-08BD2D60BA29Q37153212-FA343B27-8CBB-47AF-84F4-793F023DA872Q37950136-FD4CE8BE-C923-4428-93C6-3F9F872847D6Q37984572-AA28C825-C4A9-400F-A32F-A299CFB25D48Q37995986-8A578A5F-5AB5-4399-B585-3BD8590BCF74Q38062942-5A7230D8-F796-4003-8B84-ED37F1AB8DB9Q38074866-2228C180-F88C-4CB9-AFA4-88316B2F74F0Q38103286-C90D6B1F-0397-4554-AE83-69E169DED125Q38185937-7DD04833-9A56-436A-B71D-6B0AA76D1D14Q38202695-DA059ECB-5F14-49BD-9470-7756FD73ABBEQ38217708-73AA43F8-0EF6-421A-ACA7-61DB6A424AD9Q38604437-C1F57BE0-FEE8-41DC-A130-658399EC5A9FQ38638657-8D296243-2953-4D00-8D55-B715D32E36B7Q38680655-1D7B0C17-0A79-4A22-A7B1-943AEC79853AQ39613283-98BE27FF-833D-4E9A-9F34-F51A2660B845Q41035406-EF495EAA-4141-4031-8EC8-3740EAC631BDQ42578489-133A1B50-00F1-49FF-BEAB-94A0A5E11FE1Q42730811-74367898-E58B-474E-A042-D4E6993849F6Q51767255-55FD74FF-746F-4FEE-9644-E5E4141E13E2
P2860
Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epicutaneous allergen administ ...... lergen-specific immunotherapy?
@en
Epicutaneous allergen administ ...... lergen-specific immunotherapy?
@nl
type
label
Epicutaneous allergen administ ...... lergen-specific immunotherapy?
@en
Epicutaneous allergen administ ...... lergen-specific immunotherapy?
@nl
prefLabel
Epicutaneous allergen administ ...... lergen-specific immunotherapy?
@en
Epicutaneous allergen administ ...... lergen-specific immunotherapy?
@nl
P2093
P2860
P1433
P1476
Epicutaneous allergen administ ...... lergen-specific immunotherapy?
@en
P2093
S von Moos
Thomas M Kündig
P2860
P304
P356
10.1111/J.1398-9995.2011.02560.X
P577
2011-02-24T00:00:00Z